Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 13:53 ET | Source: Foundation for Sarcoidosis Research

The Foundation for Sarcoidosis Research Expands Board of Directors with Leaders to Help Accelerate Sarcoidosis Research, Advocacy and Patient Support

FSR announces the appointment of four new members to its Board of Directors.
April 02, 2025 20:13 ET | Source: Novartis Pharma AG

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation...
March 28, 2025 12:52 ET | Source: Novartis Pharma AG

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)...
March 19, 2025 09:00 ET | Source: Novartis Pharma AG

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

Treatment with investigational OAV101 IT led to statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in sham control armSafety findings were consistent in both treatment-naïve...
February 28, 2025 09:00 ET | Source: Novartis Pharma AG

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III...
February 11, 2025 01:15 ET | Source: Novartis Pharma AG

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in...
January 22, 2025 08:15 ET | Source: Tiny Health

Tiny Health Launches Index Predicting Child’s Gut Microbiome Age

Tiny Health launches its Maturation Index, an advanced machine learning tool that predicts a child’s gut microbiome age with 1-2 month accuracy up to age 3
January 13, 2025 01:15 ET | Source: Novartis Pharma AG

Novartis Entresto® US patent upheld by US Court of Appeals

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination...
December 10, 2024 09:00 ET | Source: Novartis Pharma AG

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between...
November 25, 2024 01:15 ET | Source: Novartis Pharma AG

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year...

Next Page keyboard_arrow_right